Our research in Immunology

Intended for healthcare professionals, scientific audiences and media.  

Pursuing pathbreaking science in Immunology

Giovanni Caforio on Bristol Myers Squibb's leadership in Immunology

Hear from our Board Chair and CEO, Giovanni Caforio, M.D., about our commitment to elevating patient care to new standards to deliver what matters most – the promise of living a better life.

 

At Bristol Myers Squibb, we are working to deliver meaningful solutions that address unmet needs in rheumatology, gastroenterology, dermatology, pulmonology and neurology. While there has been progress with medicines for immune-mediated diseases, people living with these conditions may not respond to available treatments. Many continue to endure chronic symptoms and disease progression that can take a toll on their daily life. 

 

Our goal is to restore some of what immune-mediated diseases have taken away — empowering patients and their loved ones to take back their lives.

Immunology focus areas

Our scientific innovation

Bristol Myers Squibb is focused on delivering scientific innovation with the empathy and urgency needed to advance care for people living with immune-mediated diseases. 

As we continuously build and expand our portfolio, our teams work to identify mechanisms that may reset and promote balance in the immune system, with the goal of achieving long-term remission and, ultimately, curative therapies. 

From hypothetical possibility to research reality: The innovation behind TYK2 inhibition

Discover how Bristol Myers Squibb’s pioneering research with tyrosine kinase 2 (TYK2) is changing how scientists tackle the challenge of immune-mediated diseases.


Pioneering paths forward in immunology

Hear from Jonathan Sadeh, MD, MSc, senior vice president of Immunology and Fibrosis Development at Bristol Myers Squibb, about how the company aims to build a robust immunology portfolio with pathbreaking science that addresses the unmet needs of people living with immune-mediated diseases.


Exploring pathways in immune-mediated diseases to advance patient care

Alyssa Johnsen, MD, PhD, vice president & head of clinical development, Immunology & Fibrosis at Bristol Myers Squibb, shares her perspective on the great strides that have been made in the science of modulating the body's immune response to treat disease.

Meet our Immunology researchers

Elizabeth (Liz) Colston, M.D., Ph.D. >

Clinical Development Lead, Dermatology, Central New Jersey

Richard Hargreaves, Ph.D. >

Senior Vice President, Neuroscience Thematic Research Center, Central New Jersey

Robert Plenge, M.D., Ph.D. >

Senior Vice President and Head, Immunology, Cardiovascular and Fibrosis Thematic Research Center; Head, Translational Medicine, Cambridge, Massachusetts

Jonathan Sadeh, MD, MSc  >

Senior Vice President, Head of Immunology and Fibrosis Development, Global Drug Development, Central New Jersey

Alyssa Johnsen, MD, PhD >

Vice President and Head of Clinical Development, Immunology and Fibrosis

Our presence at upcoming conferences

Rheumatology

 

American Society of Nephrology (ASN) Kidney Week 

Congress of Clinical Rheumatology (CCR) East

European Alliance of Associations for Rheumatology (EULAR) Congress

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Annual Meeting

International Congress on Systemic Lupus Erythematosus and the Korean College of Rheumatology Annual Scientific Meeting & International Symposium (LUPUS & KCR)

Lupus Academy Annual Meeting

Rheumatology Dermatology Society (RDS) Annual Meeting

American College of Rheumatology (ACR) Convergence

Congress of Clinical Rheumatology (CCR) West 

European Lupus Meeting

Immunology Annual Meeting

International Society of Nephrology (ISN) World Congress of Nephrology (WCN)

Lupus 21st Century Conference

Rheumatology Winter Clinical Symposium (RWCS)

 

 

 

Gastroenterology

 

Advances in Inflammatory Bowel Diseases (AIBD) Conference

Crohn's & Colitis Congress

European Crohn's and Colitis Organization (ECCO) Congress 

Gastroenterology Updates IBD and Liver Disease (GUILD) Conference

North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting

World Congress of Gastroenterology (WCOG)

American College of Gastroenterology (ACG) Annual Scientific Meeting

Digestive Disease Week (DDW)

Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) Annual Conference 

United European Gastroenterology (UEG) Week

 

 

 

Dermatology

 

American Academy of Dermatology (AAD) Annual Meeting

Congress of the Skin Inflammation & Psoriasis International
Network (SPIN)

Dermatology Education Foundation (DEF) Essential Resource Meeting (DERM) NP+PA Conference

Europe Dermatology Forum (EDF) Annual Meeting 

European Society for Pediatric Dermatology (ESPD) Congress

Fall Clinical Dermatology Conference

Fall Clinical Real World Dermatology (RWD)

Inflammatory Skin Disease Summit (ISDS)

International Societies for Investigative Dermatology (ISID)

Maui Derm

Maui Derm NP+PA Summer Live

Revolutionizing Atopic Dermatitis (RAD) Conference

Society of Dermatology Physician Assistants (SDPA) Annual Summer Dermatology Conference

Winter Clinical Dermatology Conference - Hawaii 

American Academy of Dermatology (AAD) Innovation Academy

Cytokines Annual Meeting

European Academy of Dermatology and Venereology (EADV) Symposium

European Society for Dermatological Research (ESDR) Annual Meeting

Fall Clinical Board Immersion

Fall Clinical Dermatology Conference for Physician Assistants (PAs) and Nurse Practitioners (NPs)

Group For Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

International Dermatology Outcome Measures (IDEOM) Annual Meeting

International Society on Atopic Dermatitis (ISAD) Symposium

Maui Derm NP+PA Fall Live

Reunión Anual de Dermatólogos Latinoamericanos (RADLA)

Society of Dermatology Physician Assistants (SDPA) Annual Fall Conference

European Academy of Dermatology and Venereology (EADV) Congress

World Congress of Dermatology

 

Neurology

 

American Academy of Neurology (AAN) Annual Meeting

Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting

European Charcot Foundation Annual Meeting

International Multiple Sclerosis Cognition Society (IMSCOGS) Annual Meeting

World Congress of Neurology (WCN)

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum

European Academy of Neurology (EAN) Congress

European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress

Treatment and Research in Multiple Sclerosis (triMS) Online Conference

 
Join us as we transform patients’ lives through science

Every day, each of us works to improve outcomes for patients fighting serious immune-mediated diseases. We're creative thinkers motivated by the practical application of our work, and innovators unafraid to step into uncharted territory. Together, we're building a better future for each other and the patients who need us most. 

Rheumatology

Over 20 years ago, Bristol Myers Squibb pioneered the science of modulating the body’s immune response to treat disease, beginning with the company’s research in rheumatoid arthritis (RA). Building on that foundation, we continue to pursue pathbreaking science across rheumatic diseases including RA, psoriatic arthritis, lupus and ankylosing spondylitis. Fueled by the possibility to help more patients, we are following the science to tailor therapies to individual needs, improve outcomes and expand treatment options.

BMS' commitment to precision medicine for patients living with immune-mediated diseases >

Hear Kellie Calderon, MD, medical director at Bristol Myers Squibb, explain the importance of collaboration and precision medicines in the study of immune-mediated disease.

Lupus: Treatments, Research and Bristol Myers Squibb's Dedication to Patients  - A Q&A With Subhashis Banerjee >

Subhashish Banerjee, MD, vice president & disease area head, Rheumatology and Dermatology at Bristol Myers Squibb, shares how the company is leveraging a pathways-based approach to advance research and ultimately elevate care for patients in need of new treatment options in systemic lupus erythematosus (SLE), also known as lupus.

Our precision-focused approach in RA and beyond: a Q&A with Dr. Sean E. Connolly >

Learn more about our work in rheumatology and what people impacted by immune-mediated diseases need to know.

Pursuing innovative approaches to advance research for psoriatic disease >

Shalabh Singhal, vice president, development program lead, Rheumatology, explains how by targeting the tyrosine kinase 2 (TYK2) pathway, researchers can further our understanding of how to improve care for psoriatic disease.

Rheumatoid arthritis >

Learn more about RA, its symptoms and its potential impact on patients. 

Psoriatic arthritis >

Learn more about psoriatic arthritis, its symptoms and its potential impact on patients. 

Juvenile idiopathic arthritis >

Learn more about juvenile idiopathic arthritis, its symptoms and its potential impact on patients.

Systemic lupus erythematosus >

Learn more about systemic lupus erythematosus, its symptoms and its potential impact on patients. 

Ankylosing spondylitis >

Learn more about ankylosing spondylitis, its symptoms and its potential impact on patients. 

Biomarkers in rheumatoid arthritis >

Learn how biomarkers in RA can provide clues to diagnosis and insights into overall prognosis and have the potential to inform treatment strategies.

TYK2 pathway >

Learn about the scientific mechanism behind the TYK2 pathway and its role in immune-mediated diseases.

Gastroenterology

Bristol Myers Squibb is pursuing innovative research to potentially change the course of gastrointestinal immune-mediated diseases, including inflammatory bowel disease (IBD) (which includes ulcerative colitis and Crohn's disease) and eosinophilic esophagitis (EoE). Our scientific innovations have the potential to provide relief and remission to people living with these conditions.

IBD: research, partnerships and Bristol Myers Squibb's dedication to patients >

Learn about Bristol Myers Squibb’s commitment to advancing IBD research for patients in need from Mark Osterman, M.D., vice president, disease area head, Gastroenterology.

Understanding the needs of people living with IBD >

Learn how Bristol Myers Squibb is committed to ongoing research in IBD.

Break the silence: shining a light on IBD >

Read a Q&A with leaders of European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA) regarding World IBD Day, and learn about the importance of advocating for patients suffering from various IBDs.

Winter's story: living with ulcerative colitis >

Learn about Winter's journey of living with ulcerative colitis for more than 20 years.

Ulcerative colitis >

Learn more about ulcerative colitis, its symptoms and effects on patients. 

Crohn's disease >

Learn more about Crohn’s disease, a gastrointestinal immune-mediated disease that affects patients worldwide.

Eosinophilic esophagitis >

Learn more about EoE, a gastrointestinal immune-mediated disease that affects patients worldwide.

S1P signaling >

Learn about the role of sphingosine-1-phosphate (S1P) signaling and its relationship to gut inflammation.

TYK2 pathway >

Learn about the scientific mechanism behind the tyrosine kinase 2 (TYK2) pathway and its role in immune-mediated diseases.

The IBD Global Assessment of Patient & Physician Unmet Needs Survey (GAPPS) is a resource for U.S. healthcare professionals to learn more about the impact of the evolving IBD treatment landscape on patients with ulcerative colitis and Crohn’s disease.

Dermatology

Through Bristol Myers Squibb’s pioneering exploration of immune pathways implicated in dermatologic conditions, our discovery team’s research is leading to the potential for safe, effective, category-defining new therapies that may address the pressing treatment gaps that continue to exist for people living with these conditions. With a highly focused pipeline, we are pursuing novel treatments for psoriasis and atopic dermatitis and exploring a broad range of serious dermatologic conditions in our early research.

Patient experience of living with psoriasis >

Learn about Royce Thomas' experience of living with psoriasis, as he speaks with Frida Dunger Johnsson, executive director of IFPA, and the importance of supporting the global community of individuals impacted by psoriatic disease.

Pioneering new paths forward in psoriasis >

Renata M. Kisa, M.D., discusses the company’s focus in dermatology research, how unmet needs drive the pipeline forward and what motivates Bristol Myers Squibb to make a difference for patients.

Becoming united: raising awareness globally on World Psoriasis Day >

Frida Dunger Johnsson, executive director of IFPA, and Janina Kostiukaite, project developer, sat down with Bristol Myers Squibb to discuss the importance of uniting to support those with psoriatic diseases. 

Understanding key psoriasis outcome measures  >

Bristol Myers Squibb is committed to educating patients and healthcare providers about psoriasis so that they can work together to determine a disease management plan.

Psoriasis >

Learn more about psoriasis, its symptoms and potential impact on patients.

Atopic dermatitis >

Learn more about atopic dermatitis, its symptoms and its potential impact on patients.

Psoriatic arthritis >

Learn more about psoriatic arthritis, its symptoms and its potential impact on patients.

TYK2 pathway >

Learn about the scientific mechanism behind the tyrosine kinase 2 (TYK2) pathway and its role in immune-mediated diseases.

Learn about the TYK2 pathway and its role in immune-mediated diseases like psoriasis.

Psoriasis treatment types >

Learning more about different types of treatment options can help people work with their healthcare providers on the approach best suited to their needs.

Neurology

At Bristol Myers Squibb, we are focused on delivering solutions that may help preserve physical and cognitive function in people living with neurological conditions like multiple sclerosis (MS). Building on our experience, we are pursuing pathbreaking science to improve care for those impacted by the disease. By helping restore some of what MS has taken away, we aim to empower people living with MS and their loved ones to take back control of their lives.

Taking back control: MS patients preserve body and mind >

Learn more about how MS patients engage in activities to help preserve their body and mind.

Family, science, community: Matt Labrecque’s experience with MS >

Hear from Matt, who works as a scientist at Bristol Myers Squibb, about his journey with MS.

MS in harmony: helping people living with MS achieve mind-body harmony through music therapy >

Bristol Myers Squibb and the American Music Therapy Association are partnering with Ben Platt to encourage people living with MS to give this unique, and fun, intervention a try.

Delivering meaningful innovations for the MS community >

Learn about how Bristol Myers Squibb is focused on delivering meaningful innovations to help, with the goal of preserving physical and cognitive function in people living with MS.

Multiple sclerosis >

Learn about the different types of MS and its potential impact on patients.

Multiple sclerosis and the brain >

Learn more about MS and how it affects the brain. 

Music therapy and multiple sclerosis >

Learn more about the relationship between MS and music therapy. 

Pulmonary Fibrosis

Bristol Myers Squibb is committed to applying expertise regarding the role of fibrosis in the development of several immune-mediated diseases to advance new treatments that go beyond symptom relief and address the underlying causes of disease.

Breathing new hope into pulmonary fibrosis research >

Hear Bruce Ellsworth, PhD, scientific executive director, Medicinal Chemistry, and Aryeh Fischer, MD, Lung Fibrosis clinical development lead, discuss how Bristol Myers Squibb is leveraging its deep expertise in medicinal chemistry and disease biology to research potential treatments for pulmonary fibrosis.

Living with Idiopathic Pulmonary Fibrosis >

Read the inspiring story of Mal Doyle, a patient living with idiopathic pulmonary fibrosis (IPF), and learn how Bristol Myers Squibb is working towards developing potential treatments to slow the progression of pulmonary fibrosis.

Lysophosphatidic acid receptor 1 (LPA1) in pulmonary fibrosis >

Learn more about Bristol Myers Squibb's commitment to developing new treatments for immune-mediated diseases with our research on the LPA1 receptor and its role in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.